Two New Patents Strengthen BLIS Global IP Position
BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
19 September 2025
Two New Patents Strengthen BLIS Global IP Position
BLIS Technologies (NZX: BLT) is pleased to announce that two new patents have been granted by the
Australian Patent Office, further strengthening BLIS’ leadership in oral probiotics and supporting its
growth strategy in global health markets.
The patents cover:
• Antiviral Applications: Protects the use of Streptococcus salivarius K12 and M18 for
defending against key upper respiratory viruses including SARS-CoV-2, Influenza A & B, and
RSV.
• Enhanced Formulations: Secures proprietary combinations of Streptococcus salivarius K12
and M18 with specific prebiotic sugars proven to enhance antimicrobial activity.
What this means for BLIS:
• Growth: Enables development of new products in high-value global health markets.
• Innovation: Validates BLIS’ R&D leadership and investment in science-backed technologies.
• Market Leadership: Strengthens BLIS’ competitive edge and supports long-term global IP
strategy.
“These patents cement BLIS’ position as a global leader in oral probiotics, unlocking new product
opportunities and protecting our science-backed innovation pipeline for long-term growth,” says
CEO Scott Johnson.
Ends
For further information, please contact:
Scott Johnson
Chief Executive Officer
+64 21 488 831
About BLIS Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at
www.blis.co.nz.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- CVT — Comvita Limited: Comvita Scheme Booklet and Notice of Meeting2025-10-14
“53 § BLIS is a small NZX listed company that develops and sells healthcare products based on strains of bacteria. The company offers BLIS K12 (an oral probiotic supplement to support ear, nose and throat health as well as for enhancing immunity and bad breath), BLIS M18 (…”
- BIF — Booster Innovation Fund: BIF – Updated Offer Documents2025-12-08
“Booster Innovation Fund21 My Better Breathing Limited Fund shareholding0–5% Company establishment2021 Sub-SectorMedical device Company stageSeed Key peopleKerri McMaster, David White DirectorsCarl Jones, Kerri McMaster Websitegoodairnosebuds.com Technology origin Auckland Univer…”
- THL — Tourism Holdings Limited: thl outlines its growth roadmap2025-08-03
“Tourism Holdings Limited 470 Oruarangi Road, Māngere, Auckland 2022 PO Box 4293, Shortland Street, Auckland 1140, New Zealand www.thlonline.com 4 August 2025 NZX | ASX | MEDIA RELEASE TOURISM HOLDINGS LIMITED (thl) THL OUTLINES ITS GROWTH ROADMAP Tourism Ho…”